Skip to content

Endocrinology

Study findings updated . AI-assisted evidence summary, not individual medical advice or a clinician endorsement.

Key findings

13.46 extra per 1000more new diabetes cases in a year in US veterans after COVID-19 vs uninfected peers

Veterans who survived COVID-19 were more likely to develop diabetes.

Among US veterans who survived the early weeks of COVID-19, the risk of a new diabetes diagnosis over the next year was 1.4 times that of uninfected veterans (hazard ratio 1.40), or 13.46 extra cases per 1000 people. The risk rose with how sick people got and appeared even in those at the lowest starting risk.

Diabetes is lifelong and raises risks for heart, kidney and eye disease, so even a modest bump across millions of infections adds up. The findings support checking for diabetes after COVID-19, especially after severe illness. Infections happened before Omicron and mostly before vaccines, in mostly older male veterans; Omicron-era studies find a much smaller link.

See the evidence

Observational study of national US Veterans Affairs health records, comparing veterans who had COVID-19 with over 4 million uninfected veterans, followed for about a year.

From the study: “people with COVID-19 exhibited an increased risk (HR 1·40, 95% CI 1·36-1·44) and excess burden (13·46, 95% CI 12·11-14·84, per 1000 people at 12 months) of incident diabetes”

13.46 extra per 1000

Xie Y et al. Risks and burdens of incident diabetes in long COVID: a cohort study. The lancet. Diabetes & endocrinology. 2022.

From the study: “Risks and burdens of post-acute outcomes increased in a graded fashion according to the severity of the acute phase of COVID-19”

13.46 extra per 1000

Xie Y et al. Risks and burdens of incident diabetes in long COVID: a cohort study. The lancet. Diabetes & endocrinology. 2022.

From the study: “the results suggested that COVID-19 was associated with an increased risk of diabetes across all risk score quartiles, including the lowest risk score quartile”

13.46 extra per 1000

Xie Y et al. Risks and burdens of incident diabetes in long COVID: a cohort study. The lancet. Diabetes & endocrinology. 2022.

14% higher riskof starting diabetes medicine after Omicron-era COVID-19, vs matched uninfected people

Omicron-era COVID-19 carried a small diabetes link that may not be real.

In national registries, teens and adults with Omicron-era COVID-19 had a 14% higher risk of starting diabetes treatment in the following months than matched people without COVID-19. The link was weaker in people boosted within the past 90 days (hazard ratio 1.08) than in those with up to two vaccine doses (1.22).

It updates the early-pandemic warning: in the Omicron era any extra diabetes risk looks small, smaller still after a recent booster, and the authors say the true effect could be near zero. Registry study where infection was also linked to unrelated 'negative control' conditions, a sign that more doctor visits, not the virus, may explain part of the rise.

See the evidence

Population-based matched cohort study using linked national registry data on people aged 16 and older diagnosed with COVID-19 from December 2021 to December 2022, followed a median of 200 days.

From the study: “individuals with COVID-19 had a 14% higher risk of subsequently initiating diabetes treatment”

14% higher risk

Qian, Jiahui et al.. New-onset diabetes following SARS-CoV-2 infection in the Omicron era: a matched cohort study.. International journal of epidemiology. 2026.

From the study: “The risk was higher for those who had received up to two COVID-19 vaccine doses compared with those who had received a booster within the last 90 days (aHR 1.22; 95% CI 1.18, 1.25 vs aHR 1.08”

14% higher risk

Qian, Jiahui et al.. New-onset diabetes following SARS-CoV-2 infection in the Omicron era: a matched cohort study.. International journal of epidemiology. 2026.

From the study: “the true causal effect could be small or even null given the potential unmeasured confounding and detection bias”

14% higher risk

Qian, Jiahui et al.. New-onset diabetes following SARS-CoV-2 infection in the Omicron era: a matched cohort study.. International journal of epidemiology. 2026.

1 in 3 hospital deathsfrom COVID-19 in England's first wave were in people with diabetes

A third of early COVID-19 hospital deaths in England involved diabetes.

Across England, 4.7% of people had type 2 diabetes and 0.4% type 1, yet people with diabetes made up a third of early in-hospital COVID-19 deaths. Allowing for age, sex, deprivation, ethnicity and region, type 1 diabetes carried 3.5 times the odds of dying in hospital with COVID-19, and type 2 twice the odds, vs people without diabetes.

Diabetes is common, so this added danger touches millions of families. It explains why doctors treat COVID-19 in people with diabetes, especially type 1, as higher risk. Data are from the first pandemic wave, before vaccines and antiviral treatments, so they may overstate risks today.

See the evidence

Whole-population study of nearly everyone registered with a family doctor in England, counting in-hospital COVID-19 deaths from March to May 2020.

From the study: “A third occurred in people with diabetes: 7434 (31·4%) in people with type 2 diabetes, 364 (1·5%) in those with type 1 diabetes”

1 in 3 hospital deaths

Barron E et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. The lancet. Diabetes & endocrinology. 2020.

From the study: “people with type 1 diabetes had 3·5 times the odds of in-hospital death with COVID-19 and people with type 2 diabetes had twice the odds, relative to people without diabetes”

1 in 3 hospital deaths

Barron E et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. The lancet. Diabetes & endocrinology. 2020.

From the study: “263 830 (0·4%) had a recorded diagnosis of type 1 diabetes, 2 864 670 (4·7%) had a diagnosis of type 2 diabetes”

1 in 3 hospital deaths

Barron E et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. The lancet. Diabetes & endocrinology. 2020.

41% less long COVIDmetformin vs placebo, started early in adults with excess weight (randomized trial)

Early metformin cut long COVID by 41% in a randomized trial.

In a US trial of 1126 adults with overweight or obesity and new COVID-19, 6.3% of those randomly assigned metformin, a cheap diabetes pill, got a long COVID diagnosis by day 300, vs 10.4% on placebo. That is an absolute drop of 4.1%. Two other drugs tested, ivermectin and fluvoxamine, showed no effect.

Long COVID has almost no proven ways to prevent it. Metformin is cheap and widely used, so researchers are testing whether early treatment helps in today's mostly vaccinated population, where results so far are mixed. Long COVID was a secondary goal in a trial run mostly before Omicron; a later trial in mostly immune adults found a smaller, less certain benefit.

See the evidence

Randomized, placebo-controlled, quadruple-blind trial at six US sites enrolling adults aged 30 to 85 with overweight or obesity between December 2020 and January 2022, followed for 10 months.

From the study: “Outpatient treatment with metformin reduced long COVID incidence by about 41%, with an absolute reduction of 4·1%, compared with placebo.”

41% less long COVID

Bramante CT et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. The Lancet. Infectious diseases. 2023.

From the study: “The cumulative incidence of long COVID by day 300 was 6·3% (95% CI 4·2-8·2) in participants who received metformin and 10·4% (7·8-12·9) in those who received identical metformin placebo”

41% less long COVID

Bramante CT et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. The Lancet. Infectious diseases. 2023.

From the study: “Overall, 93 (8·3%) of 1126 participants reported receipt of a long COVID diagnosis by day 300.”

41% less long COVID

Bramante CT et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. The Lancet. Infectious diseases. 2023.

31% higher riskof new diabetes in US kids after COVID-19, vs kids who tested negative

US kids had higher rates of new diabetes after COVID-19.

Among US children under 18, those with COVID-19 were 31% more likely to get a new diabetes diagnosis over a month later than matched kids who tested negative (399 vs 304 per 100,000 kids per year). A second database found 166% higher risk vs kids without COVID-19. In one database, 48.5% of new cases after infection came with DKA, a dangerous acid buildup.

New diabetes in a child is life-changing, and DKA can be deadly. Parents can watch for warning signs such as heavy thirst, frequent urination and weight loss after an infection, though the absolute risk stayed low. Insurance-claims study from early in the pandemic that cannot prove cause; a Danish national study found no rise in type 1 diabetes after infection.

See the evidence

CDC analysis of two large US health-insurance claims databases covering hundreds of thousands of children with COVID-19 from March 2020 to June 2021, compared with matched children.

From the study: “Diabetes risk was 166% higher in the COVID-19 group than in the non-COVID-19 group”

31% higher risk

Barrett CE et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years - United States, March 1, 2020-June 28, 2021. MMWR. Morbidity and mortality weekly report. 2022.

From the study: “diabetes incidence was 31% higher among patients aged <18 years with COVID-19 (399 per 100,000 person-years) than among those without COVID-19 (304 per 100,000 person-years”

31% higher risk

Barrett CE et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years - United States, March 1, 2020-June 28, 2021. MMWR. Morbidity and mortality weekly report. 2022.

From the study: “DKA was reported in 48.5% (IQVIA) and 40.2% (HealthVerity) of patients with COVID-19 and diabetes”

31% higher risk

Barrett CE et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years - United States, March 1, 2020-June 28, 2021. MMWR. Morbidity and mortality weekly report. 2022.

1 in 2 patientsof US adults treated for COVID-19 in ERs or hospitals had obesity

Half of US adults needing hospital care for COVID-19 had obesity.

Among 148,494 US adults diagnosed with COVID-19 in an ER or hospital at 238 hospitals, 50.8% had obesity, vs 42.4% of US adults. Risk of hospital stay, intensive care and death was lowest near the healthy-overweight line and rose with higher BMI (weight for height); obesity was linked to hospitalization and death, especially under 65.

Obesity is common in the US, so this pattern touches tens of millions. Risk climbed steadily with weight rather than switching on at one cutoff, and even overweight was linked to needing a breathing machine. Only adults who reached a hospital in the pre-vaccine year were studied, so it can't show risk for all infected adults or prove weight caused severity.

See the evidence

CDC analysis of records from 238 US hospitals covering 148,494 adults diagnosed with COVID-19 in an emergency department or inpatient visit from March to December 2020.

From the study: “One half (50.8%) of adult COVID-19 patients in this analysis had obesity, compared with 43.1% in the total PHD-SR sample and 42.4% nationally”

1 in 2 patients

Kompaniyets L et al. Body Mass Index and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death - United States, March-December 2020. MMWR. Morbidity and mortality weekly report. 2021.

From the study: “Overweight and obesity were risk factors for invasive mechanical ventilation, and obesity was a risk factor for hospitalization and death, particularly among adults aged <65 years.”

1 in 2 patients

Kompaniyets L et al. Body Mass Index and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death - United States, March-December 2020. MMWR. Morbidity and mortality weekly report. 2021.

From the study: “Among 148,494 adults who received a COVID-19 diagnosis during an emergency department (ED) or inpatient visit at 238 U.S. hospitals”

1 in 2 patients

Kompaniyets L et al. Body Mass Index and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death - United States, March-December 2020. MMWR. Morbidity and mortality weekly report. 2021.

0.7× COVID-19 deathshazard ratio, semaglutide vs placebo, among trial volunteers who caught COVID-19

Semaglutide users who caught COVID-19 were less likely to die of it.

In a trial of 17,604 adults aged 45 or older with excess weight and heart disease but no diabetes, weekly semaglutide (the drug in Wegovy) did not prevent catching COVID-19. But among those infected, 43 on semaglutide died of COVID-19 vs 65 on placebo (hazard ratio 0.66), and fewer had serious COVID-19 complications (232 vs 277).

Obesity raises COVID-19 danger and GLP-1 drugs like semaglutide are now widely used. This randomized evidence hints they may soften severe outcomes, an idea researchers are still testing. A secondary look at a heart trial with few COVID-19 deaths; comparing only those who got infected can tilt results.

See the evidence

Analysis of the SELECT randomized trial, which gave 17,604 adults with heart disease and excess weight weekly semaglutide or placebo for an average of 3.3 years, spanning the pandemic.

From the study: “Semaglutide did not reduce incident COVID-19”

0.7× COVID-19 deaths

Scirica BM et al. The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial. Journal of the American College of Cardiology. 2024.

From the study: “fewer participants treated with semaglutide had COVID-19-related serious adverse events (232 vs 277; P = 0.04) or died of COVID-19 (43 vs 65; HR: 0.66; 95% CI: 0.44-0.96)”

0.7× COVID-19 deaths

Scirica BM et al. The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial. Journal of the American College of Cardiology. 2024.

From the study: “randomized 17,604 participants ≥45 years of age with a body mass index ≥27”

0.7× COVID-19 deaths

Scirica BM et al. The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial. Journal of the American College of Cardiology. 2024.

No rise (HR 0.85)hazard ratio, type 1 diabetes in Danish kids after a positive vs only negative tests

Danish children showed no rise in type 1 diabetes after COVID-19.

Among children in Denmark, where 90% of kids were tested, those with a positive test were no more likely to be newly diagnosed with type 1 diabetes 30 days or more later than children with only negative tests (hazard ratio 0.85). The authors say type 1 diabetes need not be a special worry after a child's infection.

Type 1 is the main kind of diabetes in children. Because nearly every Danish child was tested, mild and silent infections were counted, making this a strong check on alarming claims-based findings. Covers only type 1 diabetes, not type 2, and the brief report gives few details on case numbers or years studied.

See the evidence

Prospective nationwide registry study of Danish children, comparing those with a positive SARS-CoV-2 test against those with only negative tests.

From the study: “we did not observe a higher risk of first-time diagnosis of type 1 diabetes in children 30 days or more after a positive SARS-CoV-2 test (hazard ratio 0.85; 95% CI 0.70-1.04)”

No rise (HR 0.85)

Noorzae R et al. Risk of Type 1 Diabetes in Children Is Not Increased After SARS-CoV-2 Infection: A Nationwide Prospective Study in Denmark. Diabetes care. 2023.

From the study: “Denmark had one of the highest test rates per capita in the world, and 90% of all Danish children were tested”

No rise (HR 0.85)

Noorzae R et al. Risk of Type 1 Diabetes in Children Is Not Increased After SARS-CoV-2 Infection: A Nationwide Prospective Study in Denmark. Diabetes care. 2023.

From the study: “Our data do not support that SARS-CoV-2 infection is associated with type 1 diabetes or that type 1 diabetes should be a special focus after a SARS-CoV-2 infection in children.”

No rise (HR 0.85)

Noorzae R et al. Risk of Type 1 Diabetes in Children Is Not Increased After SARS-CoV-2 Infection: A Nationwide Prospective Study in Denmark. Diabetes care. 2023.

Study-specific findings. Different populations, treatments and follow-up periods can produce different results.

Browse all 13 recorded findingsSearch the original results, comparisons and study details.
5 of 5 source groupsFindings stay together with their study.
SOURCE 054 findings

Miyashita, Koichi et al.. Increased Risk of Thyrotoxicosis After COVID-19 in Adolescents and Young Adults During the Omicron-Predominant Period: A Nationwide Matched Study.. Clinical endocrinology. 2026.

Database-recorded thyrotoxicosis diagnosis within 90 days after COVID-19 versus influenza during the Omicron-predominant period among patients without pre-existing thyroid disease

Added
RR 1.08Source [5]

Database-recorded hypothyroidism diagnosis within 90 days after COVID-19 versus influenza during the Omicron-predominant period among patients without pre-existing thyroid disease

Added
RR 1.12Source [5]
All 4 findings from this source

Thyroid hormone replacement therapy initiation within 90 days after COVID-19 versus influenza during the Omicron-predominant period among patients without pre-existing thyroid disease

Added
RR 1.22Source [5]

Database-recorded antithyroid drug initiation within 90 days after COVID-19 versus influenza during the Omicron-predominant period among individuals without pre-existing thyroid disease

Added
RR 1.06Source [5]
SOURCE 043 findings

Daher, Joviane et al.. Glucose metabolism across COVID-19 and long COVID: a longitudinal study.. Journal of the Endocrine Society. 2026.

HbA1c from pre-infection to 12 months after COVID-19 among adults without preexisting diabetes

Added
5.39% vs 5.40%; P = .435Source [4]

Change in estimated 10-year ASCVD risk after COVID-19

Added
6.7% to 7.3%; P < .001Source [4]
All 3 findings from this source

New-onset metabolic syndrome incidence across long COVID categories; persistent metabolic syndrome was more frequent with more severe long COVID

Added
18%-20%Source [4]
SOURCE 012 findings

Qian, Jiahui et al.. New-onset diabetes following SARS-CoV-2 infection in the Omicron era: a matched cohort study.. International journal of epidemiology. 2026.

New-onset diabetes treatment initiation after SARS-CoV-2 infection in Omicron era

HR 1.1495% CI: 1.12-1.17Source [1]

Risk of initiating diabetes treatment after COVID-19 during Omicron-dominant period

HR 1.1495% CI: 1.12-1.17Source [1]
SOURCE 022 findings

Lawal, Bukola et al.. Post-acute metabolic changes and risk of new-onset diabetes following COVID-19: a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.

Elevated HbA1c levels indicating impaired glycemic control

SMD 1.4495% CI: 0.36-2.52Source [2]

Increased insulin resistance measured by HOMA-IR

SMD 0.9695% CI: 0.33-1.58Source [2]
SOURCE 032 findings

Wang, Zixuan et al.. Glycemic variability and the short-term mortality of hospitalized patients with COVID-19: a meta-analysis.. Frontiers in endocrinology. 2026.

High glucose variability associated with increased short-term all-cause mortality in hospitalized COVID-19 patients

RR 2.1095% CI: 1.69-2.59Source [3]

Association in younger patients (mean age <62 years)

RR 1.78Source [3]
Browse the 12 original sourcesThe complete bibliography behind this monitor.
  1. [1]

    Qian, Jiahui et al.. New-onset diabetes following SARS-CoV-2 infection in the Omicron era: a matched cohort study.. International journal of epidemiology. 2026.

    Open original source in a new tab
  2. [2]

    Lawal, Bukola et al.. Post-acute metabolic changes and risk of new-onset diabetes following COVID-19: a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.

    Open original source in a new tab
  3. [3]

    Wang, Zixuan et al.. Glycemic variability and the short-term mortality of hospitalized patients with COVID-19: a meta-analysis.. Frontiers in endocrinology. 2026.

    Open original source in a new tab
  4. [4]

    Daher, Joviane et al.. Glucose metabolism across COVID-19 and long COVID: a longitudinal study.. Journal of the Endocrine Society. 2026.

    Open original source in a new tab
  5. [5]

    Miyashita, Koichi et al.. Increased Risk of Thyrotoxicosis After COVID-19 in Adolescents and Young Adults During the Omicron-Predominant Period: A Nationwide Matched Study.. Clinical endocrinology. 2026.

    Open original source in a new tab
  6. [6]

    Xie Y et al. Risks and burdens of incident diabetes in long COVID: a cohort study. The lancet. Diabetes & endocrinology. 2022.

    Open original source in a new tab
  7. [7]

    Barron E et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. The lancet. Diabetes & endocrinology. 2020.

    Open original source in a new tab
  8. [8]

    Bramante CT et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. The Lancet. Infectious diseases. 2023.

    Open original source in a new tab
  9. [9]

    Barrett CE et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years - United States, March 1, 2020-June 28, 2021. MMWR. Morbidity and mortality weekly report. 2022.

    Open original source in a new tab
  10. [10]

    Kompaniyets L et al. Body Mass Index and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death - United States, March-December 2020. MMWR. Morbidity and mortality weekly report. 2021.

    Open original source in a new tab
  11. [11]

    Scirica BM et al. The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial. Journal of the American College of Cardiology. 2024.

    Open original source in a new tab
  12. [12]

    Noorzae R et al. Risk of Type 1 Diabetes in Children Is Not Increased After SARS-CoV-2 Infection: A Nationwide Prospective Study in Denmark. Diabetes care. 2023.

    Open original source in a new tab

About this collection.

Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results. Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed.

Download and methodology

Download the findings and bibliography displayed in this page snapshot. Values and confidence intervals remain as reported text; this is not a pooled estimate or a systematic review. Product-label observations and editorial takeaways are excluded.

These findings may omit evidence or contain errors and have not been reviewed by a clinician. A citation or download does not establish source verification. Read the original studies for their methods and limitations.

The October 2026 COVID citation audit found errors in this collection. These downloads may still contain affected findings and bibliography entries. Read the correction record before using them.

“Added” dates record entry into the monitor, not publication or clinical review. A null original acquisition or derivation means its historical record is unknown; a current record or verification has its own observation time. The SHA-256 snapshot identifier binds the downloadable public fields. CSV includes finding rows and bibliography-only source rows; JSON includes both lists. Spreadsheet-sensitive CSV cells begin with an apostrophe for safety; JSON preserves the original text.

For attribution, cite ModernDoc and the page URL, data update date and snapshot identifier in the download. Original studies retain their own rights; this download does not grant a licence to their full text.